BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rinke A, Gress TM. Neuroendocrine Cancer, Therapeutic Strategies in G3 Cancers. Digestion. 2017;95:109-114. [PMID: 28161703 DOI: 10.1159/000454761] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 5.8] [Reference Citation Analysis]
Number Citing Articles
1 Schmidt D, Wiedenmann B. Extremely Long Survival under Combined Immunotherapy in a Metastatic Functional Neuroendocrine Neoplasia Patient. Neuroendocrinology 2018;106:381-8. [PMID: 29402823 DOI: 10.1159/000486417] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
2 Zhang C, Yu GM, Zhang M, Wu W, Gong LB. S-1 plus apatinib followed by salvage esophagectomy for irinotecan-refractory small cell carcinoma of the esophagus: A case report and review of the literature. Medicine (Baltimore) 2020;99:e18892. [PMID: 32011517 DOI: 10.1097/MD.0000000000018892] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Scoazec JY, Couvelard A; Réseau TENpath. [Classification of pancreatic neuroendocrine tumours: Changes made in the 2017 WHO classification of tumours of endocrine organs and perspectives for the future]. Ann Pathol 2017;37:444-56. [PMID: 29169836 DOI: 10.1016/j.annpat.2017.10.003] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 6.6] [Reference Citation Analysis]
4 Bundschuh RA, Habacha B, Lütje S, Essler M. Therapy of Patients with Neuroendocrine Neoplasia-Evidence-Based Approaches and New Horizons. J Clin Med 2019;8:E1474. [PMID: 31527438 DOI: 10.3390/jcm8091474] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
5 Singhal S, Patel G, Singh RB, Potdar R. Grade 3 Neuroendocrine Tumor (G3NET): An Unusual Tumor With A Histochemical Surprise. Cureus 2021;13:e19103. [PMID: 34868755 DOI: 10.7759/cureus.19103] [Reference Citation Analysis]
6 Weich A, Werner RA, Buck AK, Hartrampf PE, Serfling SE, Scheurlen M, Wester HJ, Meining A, Kircher S, Higuchi T, Pomper MG, Rowe SP, Lapa C, Kircher M. CXCR4-Directed PET/CT in Patients with Newly Diagnosed Neuroendocrine Carcinomas. Diagnostics (Basel) 2021;11:605. [PMID: 33805264 DOI: 10.3390/diagnostics11040605] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Elzein S, Bao F, Lin R, Schnickel G, Lowy AM, Botta GP. Tri-modal management of primary small cell carcinoma of the pancreas (SCCP): a rare neuroendocrine carcinoma (NEC). BMC Gastroenterol 2021;21:340. [PMID: 34479480 DOI: 10.1186/s12876-021-01901-7] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Liu AJ, Ueberroth BE, McGarrah PW, Buckner Petty SA, Kendi AT, Starr J, Hobday TJ, Halfdanarson TR, Sonbol MB. Treatment Outcomes of Well-Differentiated High-Grade Neuroendocrine Tumors. Oncologist 2021;26:383-8. [PMID: 33496040 DOI: 10.1002/onco.13686] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
9 Kiesewetter B, Raderer M. How I treat neuroendocrine tumours. ESMO Open 2020;5:e000811. [PMID: 32817134 DOI: 10.1136/esmoopen-2020-000811] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
10 Zatelli MC, Guadagno E, Messina E, Lo Calzo F, Faggiano A, Colao A, _ _. Open issues on G3 neuroendocrine neoplasms: back to the future. Endocrine-Related Cancer 2018;25:R375-84. [DOI: 10.1530/erc-17-0507] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
11 Semrau S, Agaimy A, Pavel M, Lubgan D, Schmidt D, Cavallaro A, Golcher H, Grützmann R, Fietkau R. Long-term control with chemoradiation of initially metastatic mixed adenoneuroendocrine carcinoma of the rectum: a case report. J Med Case Rep 2019;13:82. [PMID: 30902067 DOI: 10.1186/s13256-019-1995-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
12 Kiesewetter B, Raderer M. My burning issues in neuroendocrine tumours (NET). Memo 2018;11:313-6. [PMID: 30595757 DOI: 10.1007/s12254-018-0449-2] [Reference Citation Analysis]
13 Lee YI, Jeon HK, Im JW, Oh SY, Kim KB, Kim B. Primary Gastric Small Cell Carcinoma: A Case Identified as a Large Subepithelial Tumor from Invisible State in 6 Months. Clin Endosc. 2019;52:76-79. [PMID: 29976037 DOI: 10.5946/ce.2018.062] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
14 Bohnenberger H, Ströbel P. Recent advances and conceptual changes in the classification of neuroendocrine tumors of the thymus. Virchows Arch 2021;478:129-35. [PMID: 33555458 DOI: 10.1007/s00428-021-03037-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Ricciardiello F, Falco M, Tortoriello G, Riccardi F, Pellini R, Iorio B, Russo G, Longo G, Coppola C, Takeuchi T, Grimaldi A, Abate M, Scrima M, Cossu AM, Addeo R, Ottaiano A, Scarpa A, Boscaino A, Motta G, Caraglia M, Bocchetti M, Misso G. Poorly Differentiated Neuroendocrine Larynx Carcinoma: Clinical Features and miRNAs Signature-A New Goal for Early Diagnosis and Therapy? J Clin Med 2021;10:2019. [PMID: 34066893 DOI: 10.3390/jcm10092019] [Reference Citation Analysis]
16 Werner RA, Weich A, Kircher M, Solnes LB, Javadi MS, Higuchi T, Buck AK, Pomper MG, Rowe SP, Lapa C. The theranostic promise for Neuroendocrine Tumors in the late 2010s - Where do we stand, where do we go? Theranostics 2018;8:6088-100. [PMID: 30613284 DOI: 10.7150/thno.30357] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 7.0] [Reference Citation Analysis]
17 Zhang MY, He D, Zhang S. Pancreatic neuroendocrine tumors G3 and pancreatic neuroendocrine carcinomas: Differences in basic biology and treatment. World J Gastrointest Oncol 2020; 12(7): 705-718 [PMID: 32864039 DOI: 10.4251/wjgo.v12.i7.705] [Cited by in CrossRef: 1] [Article Influence: 0.5] [Reference Citation Analysis]
18 Nguyen AH, O'Leary MP, De Andrade JP, Ituarte PG, Warner SG, Melstrom LG, Kessler J, Fong Y, Li D, Singh G. Presentation and survival of gastro-entero-pancreatic neuroendocrine tumors in young adults versus older patients. Am J Surg 2021:S0002-9610(21)00513-4. [PMID: 34474917 DOI: 10.1016/j.amjsurg.2021.08.030] [Reference Citation Analysis]
19 Kang XN, Zhang XY, Bai J, Wang ZY, Yin WJ, Li L. Analysis of B-ultrasound and contrast-enhanced ultrasound characteristics of different hepatic neuroendocrine neoplasm. World J Gastrointest Oncol 2019; 11(5): 436-448 [PMID: 31139313 DOI: 10.4251/wjgo.v11.i5.436] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
20 Pelosi G, Sonzogni A, Harari S, Albini A, Bresaola E, Marchiò C, Massa F, Righi L, Gatti G, Papanikolaou N, Vijayvergia N, Calabrese F, Papotti M. Classification of pulmonary neuroendocrine tumors: new insights.Transl Lung Cancer Res. 2017;6:513-529. [PMID: 29114468 DOI: 10.21037/tlcr.2017.09.04] [Cited by in Crossref: 52] [Cited by in F6Publishing: 55] [Article Influence: 10.4] [Reference Citation Analysis]
21 Liverani C, Bongiovanni A, Mercatali L, Pieri F, Spadazzi C, Miserocchi G, Di Menna G, Foca F, Ravaioli S, De Vita A, Cocchi C, Rossi G, Recine F, Ibrahim T. Diagnostic and Predictive Role of DLL3 Expression in Gastroenteropancreatic Neuroendocrine Neoplasms. Endocr Pathol 2021;32:309-17. [PMID: 33409812 DOI: 10.1007/s12022-020-09657-8] [Reference Citation Analysis]
22 Das S, Du L, Lee CL, Arhin ND, Chan JA, Kohn EC, Halperin DM, Berlin J, LaFerriere H, Singh S, Kunz PL, Dasari A. Comparison of Design, Eligibility, and Outcomes of Neuroendocrine Neoplasm Trials Initiated From 2000 to 2009 vs 2010 to 2020. JAMA Netw Open 2021;4:e2131744. [PMID: 34705010 DOI: 10.1001/jamanetworkopen.2021.31744] [Reference Citation Analysis]
23 Ishida H, Lam AK. Pancreatic neuroendocrine neoplasms: The latest surgical and medical treatment strategies based on the current World Health Organization classification. Critical Reviews in Oncology/Hematology 2020;145:102835. [DOI: 10.1016/j.critrevonc.2019.102835] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
24 van der Zwan JM, Siesling S, van Velthuysen L, Links T, Walenkamp A, Tesselaar M. Extra-Pulmonary Neuroendocrine Carcinomas: A Population-Based Study in the Netherlands. Neuroendocrinology 2018;107:50-9. [PMID: 29945149 DOI: 10.1159/000488987] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
25 Kreppel B, Gonzalez-Carmona MA, Feldmann G, Küppers J, Moon ES, Marinova M, Bundschuh RA, Kristiansen G, Essler M, Roesch F, Gaertner FC. Fibroblast activation protein inhibitor (FAPi) positive tumour fraction on PET/CT correlates with Ki-67 in liver metastases of neuroendocrine tumours. Nuklearmedizin 2021. [PMID: 34256394 DOI: 10.1055/a-1521-8604] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
26 Özdirik B, Stueven AK, Mohr R, Geisler L, Wree A, Knorr J, Demir M, Vucur M, Loosen SH, Benz F, Reiss M, Wiedenmann B, Tacke F, Jann H, Hellberg T, Roderburg C. Analysis of miR-29 Serum Levels in Patients with Neuroendocrine Tumors-Results from an Exploratory Study. J Clin Med 2020;9:E2881. [PMID: 32899973 DOI: 10.3390/jcm9092881] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
27 Sethi A, Islam M, Moses R, Finley G. Epidemiology and Retrospective Analysis in Extrapulmonary Neuroendocrine Carcinoma. Cureus 2021;13:e12748. [PMID: 33643724 DOI: 10.7759/cureus.12748] [Reference Citation Analysis]
28 Wang WQ, Zhang WH, Gao HL, Huang D, Xu HX, Li S, Li TJ, Xu SS, Li H, Long J, Ye LY, Wu CT, Han X, Wang XH, Liu L, Yu XJ. A novel risk factor panel predicts early recurrence in resected pancreatic neuroendocrine tumors. J Gastroenterol 2021;56:395-405. [PMID: 33742253 DOI: 10.1007/s00535-021-01777-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Werner RA, Higuchi T, Pomper MG, Rowe SP. Theranostics in Oncology-Thriving, Now More than Ever. Diagnostics (Basel) 2021;11:805. [PMID: 33946670 DOI: 10.3390/diagnostics11050805] [Reference Citation Analysis]